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0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, 
compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, 
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4. Phase III with telcagepant 
5. Expert opinion 
 
Background: Migraine is a common cause of disability.  Many subjects (30-40%) do 
not get a response to the 5-HT1B/1D agonists (the triptans) commonly used in the 
treatment of migraine attacks.  Calcitonin Gene-Related Protein (CGRP) receptor 
antagonism is a new approach to the treatment of migraine attacks.  
Objectives/methods: This evaluation is of a Phase III clinical trial comparing 
telcagepant, an orally active CGRP receptor antagonist, with zolmitriptan in subjects 
during an attack of migraine. Results: Telcagepant 300 mg has a similar efficacy to 
zolmitriptan in relieving pain, phonophobia, photophobia and nausea.  Telcagepant 
was better tolerated than zolmitriptan. Conclusions: The initial Phase III clinical trial 
results with telcagepant are promising, but several further clinical trials are needed to 
determine the place of telcagepant in the treatment of migraine attacks. 
 






Over 23 million people in the US suffer from migraine, and this migraine is a major 
cause of disability and work loss [1].  The present medicines of choice in the 
treatment of migraine attacks are the triptans, which are agonists at 5-HT1B/1D 
receptors in the central nervous system and on blood vessels.  However, 30-40% of 
subjects with migraine do not respond to triptans, and those who have severe 
headache, presence of photophobia/phonophobia, and have nausea are more likely 
to be non-responders [2].   The other major problem with the triptans is that as 5-
HT1B1D receptors caused vasoconstriction, the triptans are contraindicated in subjects 
with cardiovascular disease.  Thus, the search for more effective and safer drugs for 
the treatment of migraine attack continues. 
 
Calcitonin Gene-Related Protein (CGRP) seems to have a pivotal role in migraine 
attacks.  CGRP is present in the locations involved in migraine (e.g. trigeminal 
ganglion) [3].  In animal models of migraine attacks, CGRP is released [3].  In 
subjects with migraine, the levels of CGRP are raised during an attack and fall during 
recovery, and the infusion of CGRP causes headache similar to migraine [3].  This 
suggests that CGRP receptor antagonists may be useful in the treatment of migraine 
attacks.  This evaluation briefly describes the proof-of-concept trial with the CGRP 
receptor antagonist BIBN 4096, and then the Phase II clinical trial with an orally 
active CGRP antagonist (telcagepant) during a migraine attack, and then describes 




Although BIBN 4096 (olcegepant) is a nonpeptide, selective and potent antagonist at 
CGRP receptors, it is not suitable for routine use in migraine, as it has to be given 
intravenously [4].  Nevertheless, BIBN 4096 was subjected to a clinical trial in 
migraine, to test the concept that CGRP receptor antagonism could be useful in the 
treatment of migraine.  In this trial, when a migraine attack started, the subject had to 
report to a centre, where they (n = 126) were given placebo or a range of doses of 
BIBN 4096 (0.25-10 mg) intravenously [4].  The primary efficacy end point was a 
response, defined as the reduction of severe or moderate headache to mild or 
moderate headache [4].    This response was achieved in 27% of subjects with 
placebo, and there was a much greater response of between 60-80% with BINB 
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4096 2.5 mg, 5 mg and 10 mg [4].  None of the subjects given placebo experienced 
paresthesia (“pins and needles”), but 8% of subjects given BIBN 4096 did [4].  This 
trial provided proof-of-concept that CGRP receptor antagonism relieves migraine 
attacks. 
. 
3. Phase II with telcagepant 
 
Telcagepant is a potent, orally bioavailable CGRP receptor antagonist [5].  In a 
Phase II clinical trial, telcagepant was compared to rizatriptan 10 mg, and placebo, 
with the drugs being taken orally by the 225 outpatient subjects during an attack of 
migraine [6].  Pain relief at two hours, which is the reduction of moderate or severe 
pain to no or mild pain, occurred in 46% of subject taking placebo, and this was 
increased to 68% with telcagepant 300 mg and to 70% with rizatriptan 20 mg [6].  
Sustained pain relief at 24 hours, was 24% in the placebo group, and 53% and 33% 
with telcagepant and rizatriptan, respectively [6].  Both telcagepant and rizatriptan 
were well tolerated, and there was no paraesthesia with telcagepant [6].   
 
4. Phase III with telcagepant 
 
The clinical trial showing that telcagepant is as effective as zolmitriptan in the 
treatment of acute migraine [7] is considered in this section.   
 
4.1. Methods and results 
The study involved 81 primary care or headache centres in the US and Europe.  
Subjects had to have had one to eight moderate or severe migraines attacks per 
month with or without aura in the two months prior to enrolment.  As telcagepant is 
metabolised by CYP3A4, subjects taking potent inhibitors or inducers of this enzyme 
were not permitted to enrol.  Subjects with a history or presence of cardiovascular 
disease or uncontrolled hypertension were excluded from the trial, as these 
conditions are a contraindication for zolmitriptan.   
 
The 1380 subjects enrolled were predominantly women (~85%) and white (~95%), 
and had a mean age of ~42 years old.  Only ~15% used migraine prophylaxis 
treatment, and more subjects used triptan treatment (~45%) than NSAID treatment 
(~25%) in an attack of migraine. 
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Subjects were randomised 1:1:1:1 to placebo, zolmitriptan 5 mg, telcagepant 150 mg 
or telcagepant 300 mg, and told to take their medication orally when they had a 
moderate or severe migraine attack.  A second dose was permitted if the migraine 
was still occurring after 2 hours, or if it recurred in 48 hours.  The second dose was a 
placebo for those that initially took placebo or zolmitriptan, whereas the second dose 
was a placebo or telcagepant for those who initially took telcagepant. 
 
Headache severity was recorded on a 4-point scale (no pain, mild pain, moderate 
pain, and severe pain) at the time of taking the drug or placebo, and then every 30 
minutes for 3 hours, followed by assessment after 4, 6, 8 and 24 hours.  At the same 
time, functional disability was also rated on a 4-point scale (normal, mildly impaired, 
severely impaired, and requires bed rest).  The presence of absence of nausea, 
vomiting, photophobia and phonophobia were also recorded.   
 
The primary endpoints at 2 hours were pain freedom, pain relief, no phonophobia, no 
photophobia, and no nausea.  Telcagepant was better than placebo in relieving an 
attack of migraine, assessed at each of the primary endpoints.  Thus, two hours into 
the attack, telcagepant (150 mg and 300 mg) caused more subjects to be pain free, 
have pain relief, have no phonophobia or photophobia, and have no nausea than in 
the placebo group.   
 
The secondary endpoints were 2-24 hour sustained pain freedom, total migraine 
freedom at 2 hours, and 2-24 hour total migraine freedom.  Sustained pain freedom 
(2-24 hours) was also better with telcagepant than placebo.  The higher dose of 
telcagepant (300 mg) gave higher odds ratios against placebo, suggesting a bigger 
effect, than the lower dose of telcagepant (150 mg) for all response parameters 
except nausea.  
 
Telcagepant was also compared with zolmitriptan.  Pain freedom at 2 hours occurred 
in 9.6% of placebo subjects, in 17.2% and 26.9% of telcagepant 150 and 300 mg 
subjects, respectively, and 31.3% of zolmitriptan subjects.  Pain relief was also 
similar with telcagepant 300 mg (55.0%) and zolmitriptan (56.4%), as was the lack of 
phonophobia, photophobia and nausea at 2 hours.  Total migraine freedom at 2 
hours was 22.9% and 27.2% with telcagepant 300 mg and zolmitriptan, respectively.  
The time course for elimination of pain was similar with telcagepant 300 mg and 
zolmitriptan, which was faster than telcagepant 150 mg, which was in turn greater 
than with placebo. 
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Telcagepant was better tolerated than zolmitriptan.  The overall incidence of adverse 
effects within 48 hours was lower with telcagepant 300 mg (34.1%) than with 
zolmitriptan (50.4%), and not much higher than with placebo (30.7%).  Notably, there 
was less dizziness with telcagepant (5.1%) than zolmitriptan (11.0%), less fatigue 
(4.3% vs 7.0%), less paraesthesia (1.7% vvs 5.2%), and less chest discomfort (0.9% 
vs 2.9%).  Tolerability was also measured over 14 days, but this did not differ greatly 
from the first 24 hours. 
  
4.2 Discussion 
The authors point out that their suggestion in the Phase II trial that telcagepant might 
be more effective than established treatment in providing sustained duration of pain 
relief or pain freedom up to 24 hours was not supported in this Phase III study.  
Telcagepant was well tolerated and this is an advantage over zolmitriptan.   
 
Some subjects were excluded due to contraindications for zolmitriptan, and further 
studies are required to determine the safety and efficacy of telcagepant in subjects 
with cardiovascular disease. 
 
5. Expert opinion 
 
 5.1 Onset of action 
Telcagepant and zolmitriptan were taken orally in this Phase III comparison, and the 
effectiveness was measured at two hours.  One of the most important parameters to 
measure when investigating medications for the treatment of a migraine attack is the 
onset of action.  Obviously, subjects require relief from the pain of migraine as 
quickly as possible.  Onset of action was not measured in the Phase III clinical trial 
comparing oral telcagepant and zolmitriptan, and this is an important omission.  
Future trials should determine the onset of action with telcagepant.  Also, as 
sumatriptan and zolmitriptan are available as intranasal sprays that have higher pain 
free rates than oral preparations at 15 minutes after administration [8], oral 
telcagepant should be compared to these for both onset and duration of action.  The 
manufactures (Merck Research Laboratories) should also consider whether 
telcagepant can be formulated for intranasal delivery. 
 
 5.2 Subjects taking medication which interact with zolmitriptan  
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In the Phase III study comparing telcagepant with zolmitriptan, subjects taking 
selective serotonin transporter inhibitors, dual noradrenaline and serotonin 
transporter inhibitors, and monamine oxidase inhibitors were not allowed to enrol, as 
these medicines interact with zolmitriptan, and other triptans, to cause serotonin 
toxicity.  It would be of interest to test telcagepant in these subjects to determine 
whether it provides relief of migraine in those who cannot take the triptans. 
  
 5.3 Migraine that is unresponsive to the triptans 
Only about 60% of subjects with migraine get a response at 2 hours with triptans 
(sumitriptan, zolmitriptan, naratriptan etc), and only about 20-30% of subjects are 
pain free at 2 hours [9].  It would be of interest to test telcagepant in subjects who are 
unresponsive to the triptans. 
 
 5.4 Combination therapy 
The combination of sumitriptan and naproxen sodium was more effective than 
sumitriptan alone in migraine attacks [10].  Thus, more subjects on the combination 
were pain free at 2 hours (sumitriptan/naproxen, ~32%; sumitriptan, ~24%), and had 
headache relief at 2 hours (~70% vs ~61%) [10].  The combination of sumitriptan and 
naproxen sodium was also more effective than naproxen alone [10].  The incidence 
of adverse effects was similar with sumitriptan/naproxen and sumitriptan alone [10].   
For telcagepant to be commonly used in the treatment of migraine attacks, it will 
need to be as effective and as well tolerated as the sumitriptan/naproxen 
combination.  Thus, a clinical trial comparing telcagepant to sumitriptan/naproxen in 
migraine attacks is indicated.  Alternatively, telcagepant in combination with 
naproxen could be compared to sumitriptan/naproxen in clinical trial of subjects with 
migraine  
 
As telcagepant and zolmitriptan have different mechanisms of action this could lead 
to additive benefits, and they could be considered for combination in the treatment of 
migraine attacks.  Thus, the combination of telcagepant and zolmitriptan could be 
compared to telcagepant and zolmitriptan monotherapy in subjects during a migraine 
attack. 
  
 5.5 Conclusions 
As a CGRP receptor antagonist, telcagepant represents a new approach to the 
treatment of migraine attacks.  In Phase III clinical trial, telcagepant has a similar 
efficacy to zolmitriptan, but has the advantage of being better tolerated.  Several 
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further clinical trials are needed to determine the place of telcagepant in the 
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